Liu X - Search Results

1

Neoadjuvant anthracycline followed by toripalimab combined with nab-paclitaxel in patients with early triple-negative breast cancer (NeoTENNIS): a single-arm, phase II study.

He M, Hao S, Ma L, Xiu B, Yang B, Wang Z, Xue J, Chi Y, Xiong M, Chen J, Huang X, Liu X, Wu S, Xiao Q, Huang Y, Shui R, Cao A, Li J, Di G, Yang W, Hu X, Liu G, Yu K, Jiang Y, Wang Z, Shao Z, Wu J. He M, et al. Among authors: liu x, liu g. EClinicalMedicine. 2024 Jun 28;74:102700. doi: 10.1016/j.eclinm.2024.102700. eCollection 2024 Aug. EClinicalMedicine. 2024. PMID: 39045544 Free PMC article.

2

Clinicopathological Characteristics and Survival Outcomes of Invasive Cribriform Carcinoma of Breast: A SEER Population-Based Study.

Liu XY, Jiang YZ, Liu YR, Zuo WJ, Shao ZM. Liu XY, et al. Medicine (Baltimore). 2015 Aug;94(31):e1309. doi: 10.1097/MD.0000000000001309. Medicine (Baltimore). 2015. PMID: 26252312 Free PMC article.

3

Difference in characteristics and outcomes between medullary breast carcinoma and invasive ductal carcinoma: a population based study from SEER 18 database.

Wang XX, Jiang YZ, Liu XY, Li JJ, Song CG, Shao ZM. Wang XX, et al. Oncotarget. 2016 Apr 19;7(16):22665-73. doi: 10.18632/oncotarget.8142. Oncotarget. 2016. PMID: 27009810 Free PMC article.

4

Clinical and molecular relevance of mutant-allele tumor heterogeneity in breast cancer.

Ma D, Jiang YZ, Liu XY, Liu YR, Shao ZM. Ma D, et al. Breast Cancer Res Treat. 2017 Feb;162(1):39-48. doi: 10.1007/s10549-017-4113-z. Epub 2017 Jan 16. Breast Cancer Res Treat. 2017. PMID: 28093659

5

Mixed invasive ductal and lobular carcinoma has distinct clinical features and predicts worse prognosis when stratified by estrogen receptor status.

Xiao Y, Ma D, Ruan M, Zhao S, Liu XY, Jiang YZ, Shao ZM. Xiao Y, et al. Sci Rep. 2017 Sep 4;7(1):10380. doi: 10.1038/s41598-017-10789-x. Sci Rep. 2017. PMID: 28871133 Free PMC article.

6

Decreased survival in patients with carcinoma of axillary tail versus upper outer quadrant breast cancers: a SEER population-based study.

Gou ZC, Liu XY, Xiao Y, Zhao S, Jiang YZ, Shao ZM. Gou ZC, et al. Cancer Manag Res. 2018 May 14;10:1133-1141. doi: 10.2147/CMAR.S165291. eCollection 2018. Cancer Manag Res. 2018. PMID: 29795985 Free PMC article.

7

Clinicopathological characteristics and treatment outcomes of occult breast cancer: a SEER population-based study.

Ge LP, Liu XY, Xiao Y, Gou ZC, Zhao S, Jiang YZ, Di GH. Ge LP, et al. Cancer Manag Res. 2018 Oct 9;10:4381-4391. doi: 10.2147/CMAR.S169019. eCollection 2018. Cancer Manag Res. 2018. PMID: 30349371 Free PMC article.

8

Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.

Liu XY, Ma D, Xu XE, Jin X, Yu KD, Jiang YZ, Shao ZM. Liu XY, et al. Theranostics. 2018 Dec 8;8(22):6386-6399. doi: 10.7150/thno.29164. eCollection 2018. Theranostics. 2018. PMID: 30613307 Free PMC article.

9

Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer.

Zhao S, Liu XY, Jin X, Ma D, Xiao Y, Shao ZM, Jiang YZ. Zhao S, et al. Among authors: liu xy. Theranostics. 2019 Jul 9;9(17):4935-4945. doi: 10.7150/thno.35730. eCollection 2019. Theranostics. 2019. PMID: 31410192 Free PMC article.

10

SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.

Liu XY, Jiang W, Ma D, Ge LP, Yang YS, Gou ZC, Xu XE, Shao ZM, Jiang YZ. Liu XY, et al. Theranostics. 2020 Aug 29;10(24):10940-10956. doi: 10.7150/thno.45207. eCollection 2020. Theranostics. 2020. PMID: 33042263 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

136,988 results

Search Page

Filters